Frontiers in Cardiovascular Medicine (May 2023)

Corrigendum: Cost-effectiveness of adding empagliflozin to the standard therapy for Heart Failure with Preserved Ejection Fraction from the perspective of healthcare systems in China

  • Yaohui Jiang,
  • Jun Xie

DOI
https://doi.org/10.3389/fcvm.2023.1205721
Journal volume & issue
Vol. 10

Abstract

Read online

No abstracts available.

Keywords